Quadrant Capital Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Quadrant Capital Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-175	Closed	-$17.8K	–	2788
2023 Q2	$17.8K	Sell	175 -93	-35%	-$8.8K	﹤0.01%	1770
2023 Q1	$24.4K	Hold	268	–	–	﹤0.01%	1591
2022 Q4	$10.2K	Sell	268 -17	-6%	-$585	﹤0.01%	1941
2022 Q3	$7K	Sell	285 -5,600	-95%	-$155K	﹤0.01%	2048
2022 Q2	$179K	Sell	5,885 -19,997	-77%	-$597K	0.02%	457
2022 Q1	$848K	Buy	25,882 +5,856	+29%	+$174K	0.1%	151
2021 Q4	$528K	Buy	20,026 +20,013	+153,946%	+$1.55M	0.06%	203
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	2436
2021 Q2	$2K	Buy	13 +3	+30%	+$339	﹤0.01%	2182
2021 Q1	$1K	Sell	10 -15	-60%	-$1.75K	﹤0.01%	2337
2020 Q4	$3K	Buy	25 +15	+150%	+$1.97K	﹤0.01%	1892
2020 Q3	$1K	Sell	10 -6	-38%	-$750	﹤0.01%	2107
2020 Q2	$2K	Buy	+16	New	+$2.43K	﹤0.01%	1984

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quadrant Capital Group's RETA Position: Q3 2023 in Review

Quadrant Capital Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 175 shares — an estimated $17.8K sold.

Quadrant Capital Group first reported a position in RETA in Q2 2020 and held it in 13 quarters. The position peaked at $848K in Q1 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Quadrant Capital Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Quadrant Capital Group sold 175 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $17.8K.
Quadrant Capital Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 13 quarters.
Quadrant Capital Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $848K in Q1 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Quadrant Capital Group's 13F filing for Q3 2023, filed 14 Nov 2023.